Gland Pharma receives approval for Eribulin Mesylate Injection

Gland Pharma Limited (Gland or Company), a generic injectable-focused pharmaceutical company, has received approval from the United States Food and Drug Administration (USFDA) for Eribulin Mesylate Injection, 0.5 mg/mL Single Dose Vial (Product).

The Product is expected to be the first generic approval on the market, and the Company expects to launch this product in the near term through its marketing partner.

The Product has US sales of approximately USD 92 million for twelve months ending in February 2024, according to IQVIA.

The Company is co-developing several complex injectables, including this Product, with Orbicular Pharmaceutical Technologies Private Limited.

Shares of Gland Pharma Limited was last trading in BSE at Rs. 1755.15 as compared to the previous close of Rs. 1774.50. The total number of shares traded during the day was 3418 in over 500 trades.

The stock hit an intraday high of Rs. 1820.00 and intraday low of 1746.00. The net turnover during the day was Rs. 6035286.00.

Source : Equity Bulls

Keywords

GlandPharma INE068V01023 Approval EribulinMesylateInjection